Insmed Incorporated (INSM)
|52 Week Range||16.04-28.94|
|1y Target Est||-|
|DCF Unlevered||INSM DCF ->|
|DCF Levered||INSM LDCF ->|
|Debt / Equity||1783.36%||Strong Buy|
Upgrades & Downgrades
Latest INSM news
Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases ...
24 March 2023
—Data from Retrospective Study Evaluating the Association Between Hospitalization Burden and Delay in Diagnosis of Nontuberculous Mycobacterial (NTM) Lung Disease Among Patients with Chronic Obstructi...
Insmed Incorporated (INSM) Q4 2022 Earnings Call Transcript
23 February 2023
Insmed Incorporated (NASDAQ:INSM ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Eleanor Barisser - IR Will Lewis - Chair and CEO Sara Bonstein - CFO Conference Ca...
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
23 February 2023
Insmed (INSM) delivered earnings and revenue surprises of -20% and 9.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe Insmed (INSM) Could Rally 98.26%: Here's is How to Trade
24 January 2023
The mean of analysts' price targets for Insmed (INSM) points to a 98.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...
Insmed To Present at the Nasdaq 47th Investor Conference
30 November 2022
BRIDGEWATER, N.J. , Nov. 30, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated (INSM) Q3 2022 Earnings Call Transcript
27 October 2022
Insmed Incorporated (NASDAQ:INSM ) Q3 2022 Earnings Conference Call October 27, 2022 8:30 AM ET Company Participants Will Lewis - Chair & CEO Sara Bonstein - CFO Eleanor Barisser - IR Conference Call ...
Why Insmed's Shares Fell 14.7% on Wednesday
19 October 2022
The biotech company is raising money to help it launch another drug, but it's diluting current shareholders in the process.
Insmed (INSM) Upgraded to Buy: What Does It Mean for the Stock?
4 October 2022
Insmed (INSM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Insmed Incorporated (INSM) CEO Will Lewis on Q2 2022 Results - Earnings Call Transcript
5 August 2022
Insmed Incorporated (NASDAQ:INSM ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Eleanor Barisser - Investor Relations Will Lewis - Chair & Chief Executive Officer Sa...
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >